Stocks · News reference
Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.65) per share which beat the analyst consensus estimate of $(0.73) by 10.96 percent. This is unchanged from the same period last year.
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-08-27 AccNo: 0001999480-26-000024 Size: 165 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 9.01: Financial Statements and Exhibits
Read original at edgarAlto Neuroscience, Inc. (NYSE: ANRO), a clinical-stage biopharmaceutical company developing novel precision medicines for neuropsychiatric disorders, today announced the promotion of Nick Smith to president and chief
Read original at benzingaHC Wainwright & Co. analyst Patrick R. Trucchio maintains Alto Neuroscience (NYSE:ANRO) with a Buy and raises the price target from $50 to $55.
Read original at benzingaWedbush analyst Laura Chico maintains Alto Neuroscience (NYSE:ANRO) with a Neutral and raises the price target from $24 to $26.
Read original at benzinga